
    
      PRIMARY OBJECTIVE:

      To assess in a preliminary fashion the feasibility and efficacy of ibrutinib in combination
      with nivolumab in patients with previously-treated metastatic renal cell cancer (mRCC).

      SECONDARY OBJECTIVE:

      To evaluate the safety of the combination of ibrutinib and nivolumab in patients with
      previously treated mRCC.
    
  